(Q39405008)

11 September 2017

title

Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice (English)

1 reference

11 September 2017

5

Jeanette H. W. Leusen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22285696

23 December 2024

author name string

Peter Boross

1

1 reference

11 September 2017

Agnieszka Pastula

3

1 reference

11 September 2017

J. H Marco Jansen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22285696

23 December 2024

Cees E. van der Poel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22285696

23 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22285696

23 December 2024

publication date

23 January 2012

1 reference

full work available at URL

11 September 2017

https://api.elsevier.com/content/article/PII:S0165247812000065?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

https://api.elsevier.com/content/article/PII:S0165247812000065?httpAccept=text/plain

23 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

23 December 2024

1 reference

11 September 2017

volume

143

1 reference

11 September 2017

issue

1

1 reference

11 September 2017

page(s)

44-52

1 reference

Antigenic modulation and rituximab resistance

11 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes

23 December 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

23 December 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

23 December 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes

23 December 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia

23 December 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity

23 December 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models

23 December 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

What is trogocytosis and what is its purpose?

23 December 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response

23 December 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner

23 December 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

B cells acquire antigen from target cells after synapse formation

23 December 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation.

23 December 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving

23 December 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

23 December 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

23 December 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

23 December 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Complement activation determines the therapeutic activity of rituximab in vivo.

23 December 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells.

23 December 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab

23 December 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

The mechanisms of action of rituximab in the elimination of tumor cells

23 December 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

23 December 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

23 December 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

23 December 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

23 December 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

23 December 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

23 December 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Fc receptor endocytosis is controlled by a cytoplasmic domain determinant that actively prevents coated pit localization

23 December 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Differences in endocytosis mediated by FcγRIIA and FcγRIIB2.

23 December 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis

23 December 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG.

23 December 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Capture of plasma membrane fragments from target cells by trogocytosis requires signaling in T cells but not in B cells.

23 December 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

23 December 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity

23 December 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.

23 December 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

23 December 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

23 December 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

23 December 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

Complement: help or hindrance?

23 December 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.IMLET.2012.01.004

23 December 2024

Identifiers

1 reference

11 September 2017

1 reference